IL6 and non-small cell lung carcinoma: Remarkably, IL-6 ‘CC + GC’ genotypes amplified the NSCLC risk in the dominant model (adjusted, OR = 2.34, p = 0.015), and IL-6 ‘GC’ genotype raised the NSCLC risk in the overdominant model (adjusted, OR 2.1, p = 0.033).